Experimental drug Brentuximab Vedotin (SGN-35) achieved tumor volume reductions in 94% of Relapsed or Refractory Hodgkin Lymphoma patients while 34% of them achieved complete remission, Seattle Genetics reported after completing a Pivotal Clinical Trial. The company expects to submit the medication to the FDA (Food and Drug Administration) for approval during the first quarter of 2011 and to European regulators during the first half of 2011. Brentuximab vedotin is an ADC (antibody-drug conjugate). It targets a defining marker of Hodgkin lymphoma - CD30...
More...
More...